Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases.

Empaveli (pegcetacoplan) is a prescription drug that treats paroxysmal nocturnal hemoglobinuria (PNH) by preventing the destruction of red blood cells in your blood vessels, liver, and spleen.

Apellis制药公司（NASDAQ:APLS）副总裁兼首席会计官James George ...

Enable Injections announced today that it received CE mark approval for its EnFuse syringe transfer system for drug delivery.

In its approved use in PNH, Fabhalta already competes with Empaveli, a twice-weekly infusion from Apellis Pharmaceuticals that blocks the complement system protein C3. The two drugs could also ...

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s ...

The company also generated $98.1 million from EMPAVELI® (pegcetacoplan). Apellis submitted a supplemental new drug application for EMPAVELI aimed at treating C3 glomerulopathy and primary immune ...

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With a high ...

Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials ...